Weight Loss News and Research

Latest Weight Loss News and Research

Bodies resist weight loss efforts when food intake is reduced drastically

If you've been trying to lose weight and suspect your body's working against you, you may be right, according to a University of Illinois study published in Obesity.

24 Jun 2011

Reductions in obesity-related medical costs offset cost of gastric banding surgery within 2.25 years

Allergan, Inc. today announced a new study published in the peer-reviewed journal Surgery for Obesity and Related Diseases that found the cost of a gastric banding weight-loss surgery procedure, such as Allergan's LAP-BAND Adjustable Gastric Banding System, was offset by reductions in obesity-related medical costs within 2.25 years for surgery eligible patients with diabetes, and within four years of the procedure for all surgery eligible patients.

23 Jun 2011

Fat substituted snack foods may contribute to weight gain

Fat substitutes used in popular snack foods to help people control weight may have the opposite effect, according to Purdue University research.

23 Jun 2011

Foods and lifestyles that cause most weight gain: Study

New research shows that eating more potato chips and French fries and watching too much TV are likely to lead to a bigger weight gain over the years than the weight change associated with eating more of other foods.

23 Jun 2011

Multiple abstracts on QNEXA long-term clinical study to be presented at ADA 2011

VIVUS, Inc. today announced that multiple abstracts have been accepted for presentation at the upcoming American Diabetes Association (ADA) meeting to be held June 24th to June 28th, 2011, at the San Diego Convention Center, San Diego, CA.

22 Jun 2011

Gastric bypass surgery reduces inflammation linked with cancer and diabetes

New research shows that gastric bypass significantly reduces the inflammation associated with diseases including cancer and diabetes - more proof of the overall health benefits of such surgery beyond weight loss.

22 Jun 2011

TESARO secures $101M in Series B financing

TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that it has secured $101 million in a Series B financing to advance and expand the Company's cancer product portfolio.

21 Jun 2011

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced today that the European Commission has granted marketing authorization to BYDUREON.

21 Jun 2011

Lorcaserin Phase 3 trial data on type 2 diabetes to be presented at ADA 2011

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that lorcaserin data from the Phase 3 BLOOM-DM trial will be presented in poster sessions at the American Diabetes Association's (ADA) 71st Scientific Sessions in San Diego, California.

21 Jun 2011

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA injection and SYMLIN injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.

21 Jun 2011

Synthetic fat substitutes could contribute to weight gain and obesity

Synthetic fat substitutes used in low-calorie potato chips and other foods could backfire and contribute to weight gain and obesity, according to a study published by the American Psychological Association.

21 Jun 2011

Valencell receives $5.5M in Series B venture investment

Valencell, an innovator in mobile health and fitness technology, announced today that it has received $5.5 million in Series B venture investment. The round was led by Best Buy Capital, the investment group of Best Buy Co., Inc., with participation from Series A investors TDF and True Ventures.

20 Jun 2011

Positive results from vismodegib Phase II study on advanced basal cell carcinoma

Genentech, a member of the Roche Group, announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

20 Jun 2011

Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that positive data are being presented by its collaborator Genentech, a member of the Roche Group, from a pivotal Phase II clinical trial conducted by Roche and Genentech of vismodegib in patients with advanced basal cell carcinoma, an often life-threatening form of skin cancer that can have disfiguring and debilitating effects.

20 Jun 2011

Surgery plus exercise and diet might help reduce weight in obese people

Each year more than 200,000 people with morbid obesity undergo gastric bypass surgery, but research shows that more than half of patients regain at least 20 percent of the weight lost.

18 Jun 2011

Encouraging results from ReShape Duo Phase 1 study for treatment of obesity

ReShape Medical, Inc. today announces results of its U.S. Phase 1 investigational clinical study. This feasibility study of thirty subjects assessed the safety and effectiveness of the ReShape Duo in conjunction with lifestyle modification in patients with a body mass index of 30-40.

17 Jun 2011

Children use self-induced vomiting as weight-loss strategy: Study

Children as young as ten are making themselves vomit in order to lose weight and the problem is more common in boys than girls, according to a study of nearly 16,000 school pupils published online early, ahead of print publication, by the Journal of Clinical Nursing.

16 Jun 2011

Study finds no link between anxiety, depression and weight loss after bariatric surgery

Depression and anxiety do not seem to interfere with the amount of weight loss or the improvement of obesity-related conditions after bariatric surgery, according to a new study of more than 25,000 patients presented here at the 28th Annual Meeting of the American Society for Metabolic & Bariatric Surgery.

16 Jun 2011

Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists

Today, Zealand Pharma, a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim, one of the world's leading pharmaceutical companies, jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.

16 Jun 2011

Magical thinking may help consumers cope with stressful situations

Magical thinking, usually dismissed as na-ve and irrational, can actually help consumers cope with stressful situations like trying to lose weight, according to a new study in the Journal of Consumer Research.

16 Jun 2011